FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Felmingham

Research Profile

Procedures

Chemicals & Drugs

Living Beings

Disorders

Physiology

Geographic Areas

Great Britain

Co-author Network

Publications

TOP 3
Ian Morrissey; Kirsty Maher; Laura Williams; Jemma Shackcloth; David Felmingham; Rosy Reynolds
Non-susceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections in the UK and Ireland, 1999-2007.
David J Farrell; David Felmingham; Jemma Shackcloth; Laura Williams; Kirsty Maher; Russell Hope; David M Livermore; Robert C George; Geraldine Brick; Siobhan Martin; Rosy Reynolds
Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007.
David Felmingham; Rafael Cantón; Stephen G Jenkins
Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Felmingham (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Ian Morrissey; Kirsty Maher; Laura Williams; Jemma Shackcloth; David Felmingham; Rosy Reynolds
Non-susceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections in the UK and Ireland, 1999-2007.
The Journal of antimicrobial chemotherapy 2008;62 Suppl 2():ii97-103.
2008: David J Farrell; David Felmingham; Jemma Shackcloth; Laura Williams; Kirsty Maher; Russell Hope; David M Livermore; Robert C George; Geraldine Brick; Siobhan Martin; Rosy Reynolds
Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007.
The Journal of antimicrobial chemotherapy 2008;62 Suppl 2():ii87-95.
2007: David Felmingham; Rafael Cantón; Stephen G Jenkins
Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004.
The Journal of infection 2007;55(2):111-8.
2006: David M Livermore; Rosy Reynolds; Peter Stephens; Georgia Duckworth; David Felmingham; Alan P Johnson; Stephen Murchan; Olive Murphy; Usha Gungabissoon; Pauline Waight; Richard Pebody; Jemma Shackcloth; Marina Warner; Laura Williams; Robert C George
Trends in penicillin and macrolide resistance among pneumococci in the UK and the Republic of Ireland in relation to antibiotic sales to pharmacies and dispensing doctors.
International journal of antimicrobial agents 2006;28(4):273-9.
2006: David Felmingham; David J Farrell
In vitro activity of telithromycin against Gram-negative bacterial pathogens.
The Journal of infection 2006;52(3):178-80.
2005: David Felmingham; Anthony R White; Michael R Jacobs; Peter C Appelbaum; James Poupard; Linda A Miller; Reuben N Grüneberg
The Alexander Project: the benefits from a decade of surveillance.
The Journal of antimicrobial chemotherapy 2005;56 Suppl 2():ii3-ii21.
2005: David J Farrell; Ian Morrissey; Sarah Bakker; Sylvie Buckridge; David Felmingham
Global distribution of TEM-1 and ROB-1 beta-lactamases in Haemophilus influenzae.
The Journal of antimicrobial chemotherapy 2005;56(4):773-6.
2005: David J Farrell; David Felmingham
The PROTEKT global study (year 4) demonstrates a continued lack of resistance development to telithromycin in Streptococcus pneumoniae.
The Journal of antimicrobial chemotherapy 2005;56(4):795-7.
2005: Daryl Hoban; Fernando Baquero; Vaughan Reed; David Felmingham
Demographic analysis of antimicrobial resistance among Streptococcus pneumoniae: worldwide results from PROTEKT 1999-2000.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2005;9(5):262-73.
2004: I Harding; David Felmingham
PROTEKT years 1-3 (1999-2002): study design and methodology.
Journal of chemotherapy (Florence, Italy) 2004;16 Suppl 6():9-18.
2004: David Felmingham; Jemma Shackcloth; Glenn Tillotson
BSAC Respiratory Resistance Surveillance Programme (2002-2003): comparative susceptibility of Streptococcus pneumoniae, cultured from patients in Great Britain and Ireland with community-acquired lower respiratory tract infection, to gemifloxacin.
The Journal of antimicrobial chemotherapy 2004;54(3):698-9.
2004: Joseph E Dohar; Rafael Cantón; Robert Cohen; David John Farrell; David Felmingham
Activity of telithromycin and comparators against bacterial pathogens isolated from 1,336 patients with clinically diagnosed acute sinusitis.
Annals of clinical microbiology and antimicrobials 2004;3():15.
2004: David J Farrell; Ian Morrissey; Sarah Bakker; Sylvie Buckridge; David Felmingham
In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.
Antimicrobial agents and chemotherapy 2004;48(8):3169-71.
2004: Donald E Low; David Felmingham; Steve D Brown; Manickam Rangaraju; Roomi Nusrat
Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections.
The Journal of infection 2004;49(2):115-25.
2004: David J Farrell; David Felmingham
Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003.
Antimicrobial agents and chemotherapy 2004;48(5):1882-4.
2004: David J Farrell; Ian Morrissey; Sarah Bakker; Louise Morris; Sylvie Buckridge; David Felmingham
Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance.
Journal of clinical microbiology 2004;42(2):764-8.
2004: David Felmingham
Comparative antimicrobial susceptibility of respiratory tract pathogens.
Chemotherapy 2004;50 Suppl 1():3-10.
2004: Matsuhisa Inoue; Nam Yong Lee; Seto Wing Hong; Kyungwon Lee; David Felmingham
PROTEKT 1999-2000: a multicentre study of the antibiotic susceptibility of respiratory tract pathogens in Hong Kong, Japan and South Korea.
International journal of antimicrobial agents 2004;23(1):44-51.
2004: David Felmingham; David J Farrell; Ralf Rene Reinert; Ian Morrissey
Antibacterial resistance among children with community-acquired respiratory tract infections (PROTEKT 1999-2000).
The Journal of infection 2004;48(1):39-55.
2003: Rosy Reynolds; Jemma Shackcloth; David Felmingham; Alasdair P MacGowan
Antimicrobial susceptibility of lower respiratory tract pathogens in Great Britain and Ireland 1999-2001 related to demographic and geographical factors: the BSAC Respiratory Resistance Surveillance Programme.
The Journal of antimicrobial chemotherapy 2003;52(6):931-43.
2003: Rosy Reynolds; Jemma Shackcloth; David Felmingham; Alasdair P MacGowan
Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: the BSAC Respiratory Resistance Surveillance Programme.
The Journal of antimicrobial chemotherapy 2003;52(6):925-30.
2003: Michael R Jacobs; David Felmingham; Peter C Appelbaum; Reuben N Grüneberg
The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
The Journal of antimicrobial chemotherapy 2003;52(2):229-46.
2003: David J Farrell; Stephen Douthwaite; Ian Morrissey; Sarah Bakker; Jacob Poehlsgaard; Lene Jakobsen; David Felmingham
Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study.
Antimicrobial agents and chemotherapy 2003;47(6):1777-83.
2003: Daryl Hoban; Ken Waites; David Felmingham
Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study.
Diagnostic microbiology and infectious disease 2003;45(4):251-9.
2003: Ian Morrissey; David J Farrell; Sarah Bakker; Sylvie Buckridge; David Felmingham
Molecular characterization and antimicrobial susceptibility of fluoroquinolone-resistant or -susceptible Streptococcus pneumoniae from Hong Kong.
Antimicrobial agents and chemotherapy 2003;47(4):1433-5.
2003: Caio Mendes; M E Marin; F Quiñones; J Sifuentes-Osornio; C Cuilty Siller; M Castanheira; CM Zoccoli; H López; A Súcari; F Rossi; G Barriga Angulo; A J A Segura; C Starling; I Mimica; David Felmingham
Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000).
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2003;7(1):44-61.
2003: David J Farrell; Ian Morrissey; D De Rubeis; Marion Robbins; David Felmingham
A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection.
The Journal of infection 2003;46(2):94-100.
2002: Daryl Hoban; David Felmingham
The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections.
The Journal of antimicrobial chemotherapy 2002;50 Suppl S1():49-59.
2002: David J Farrell; Ian Morrissey; Sarah Bakker; David Felmingham
Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study.
The Journal of antimicrobial chemotherapy 2002;50 Suppl S1():39-47.
2002: David Felmingham; Ralf Rene Reinert; Yoichi Hirakata; Arne C Rodloff
Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin.
The Journal of antimicrobial chemotherapy 2002;50 Suppl S1():25-37.
2002: David Felmingham
The need for antimicrobial resistance surveillance.
The Journal of antimicrobial chemotherapy 2002;50 Suppl S1():1-7.
2002: Michael R Jacobs; Saralee Bajaksouzian; Anne Windau; Peter C Appelbaum; Gengrong Lin; David Felmingham; Christine Dencer; Laura M Koeth; Mendel E Singer; Caryn E Good
Effects of various test media on the activities of 21 antimicrobial agents against Haemophilus influenzae.
Journal of clinical microbiology 2002;40(9):3269-76.
2002: David Felmingham; C Feldman; W Hryniewicz; keith klugman; S Kohno; Donald E Low; C Mendes; Arne C Rodloff
Surveillance of resistance in bacteria causing community-acquired respiratory tract infections.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2002;8 Suppl 2():12-42.
2001: David J Farrell; Ian Morrissey; Sarah Bakker; David Felmingham
Detection of macrolide resistance mechanisms in Streptococcus pneumoniae and Streptococcus pyogenes using a multiplex rapid cycle PCR with microwell-format probe hybridization.
The Journal of antimicrobial chemotherapy 2001;48(4):541-4.
2001: David Felmingham; G Zhanel; D Hoban
Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens.
The Journal of antimicrobial chemotherapy 2001;48 Suppl T1():33-42.
2001: David Felmingham; D F Brown
Instrumentation in antimicrobial susceptibility testing.
The Journal of antimicrobial chemotherapy 2001;48 Suppl 1():81-5.
2000: David Felmingham; Y Tesfaslasie; CJ Burley; R G Masterton
Penicillin resistance in pneumococci.
The Journal of antimicrobial chemotherapy 2000;45(5):710-1.
2000: David Felmingham
Respiratory pathogens: assessing resistance patterns in Europe and the potential role of grepafloxacin as treatment of patients with infections caused by these organisms.
The Journal of antimicrobial chemotherapy 2000;45():1-8.
2000: David Felmingham; Reuben N Grüneberg
The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections.
The Journal of antimicrobial chemotherapy 2000;45(2):191-203.
1999: DL Butler; R C Gagnon; Linda A Miller; James Poupard; David Felmingham; Reuben N Grüneberg
Differences between the activity of penicillin, amoxycillin, and co-amoxyclav against 5,252 Streptococcus pneumoniae isolates tested in the Alexander Project 1992-1996.
The Journal of antimicrobial chemotherapy 1999;43(6):777-82.
1998: Reuben N Grüneberg; David Felmingham; I Harding; S B Shrimpton; A Nathwani
The Nearchus project: antibiotic susceptibility of respiratory pathogens and clinical outcome in lower respiratory tract infections at 27 centres in the UK.
International journal of antimicrobial agents 1998;10(2):127-33.
1998: David Felmingham; MJ Robbins; Y Tesfaslasie; I Harding; S Shrimpton; Reuben N Grüneberg
Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995-1996 cold season.
The Journal of antimicrobial chemotherapy 1998;41(3):411-5.
1997: Geoff L Ridgway; H Salman; MJ Robbins; C Dencer; David Felmingham
The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.
The Journal of antimicrobial chemotherapy 1997;40 Suppl A():31-4.
1997: David Felmingham; MJ Robbins; K Ingley; I Mathias; H Bhogal; A Leakey; Geoff L Ridgway; Reuben N Grüneberg
In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.
The Journal of antimicrobial chemotherapy 1997;39 Suppl B():43-9.
1996: David Felmingham; MJ Robbins; C Dencer; A Nathwani; Reuben N Grüneberg
Antimicrobial susceptibility of community-acquired bacterial lower respiratory tract pathogens.
The Journal of antimicrobial chemotherapy 1996;38(4):747-51.
1996: Reuben N Grüneberg; David Felmingham
Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens.
Diagnostic microbiology and infectious disease 1996;25(4):169-81.
1995: R M Heylen; A P R Wilson; M Hichens; David Felmingham; A Webb; C W Pattison; Wilfred B Pugsley
Antibiotic prophylaxis in cardiac surgery: factors associated with potentially toxic serum concentrations of gentamicin.
The Journal of antimicrobial chemotherapy 1995;35(5):657-67.
1995: R M Heylen; A P R Wilson; M Hichens; David Felmingham; A Webb; C W Pattison; Wilfred B Pugsley
Clearance of gentamicin during cardiac surgery.
The Journal of antimicrobial chemotherapy 1995;35(5):649-55.
1994: David Felmingham; MJ Robbins; G Ghosh; K Cooper
Disc diffusion susceptibility testing with ceftriaxone.
The Journal of antimicrobial chemotherapy 1994;33(4):883-4.
1994: David Felmingham; MJ Robbins; G Ghosh; H Bhogal; M D Mehta; A Leakey; S Clark; C A Dencer; Geoff L Ridgway; Reuben N Grüneberg
An in vitro characterization of cefditoren, a new oral cephalosporin.
Drugs under experimental and clinical research 1994;20(4):127-47.
1993: David Felmingham
Towards the ideal glycopeptide.
The Journal of antimicrobial chemotherapy 1993;32(5):663-6.
1993: S B Shrimpton; M Milmoe; A P R Wilson; David Felmingham; S Drayan; C Barrass; Reuben N Grüneberg; Geoff L Ridgway
Audit of prescription and assay of aminoglycosides in a UK teaching hospital.
The Journal of antimicrobial chemotherapy 1993;31(4):599-606.
1992: David Felmingham; A P R Wilson; A I Quintana; Reuben N Grüneberg
Enterococcus species in urinary tract infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1992;15(2):295-301.
1992: David Felmingham; MJ Robbins
In vitro activity of lomefloxacin and other antimicrobials against bacterial enteritis pathogens.
Diagnostic microbiology and infectious disease 1992;15(4):339-43.
1991: David Felmingham; MJ Robbins; M Sanghrajka; A Leakey; Geoff L Ridgway
The in vitro activity of some 14-, 15- and 16- membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum.
Drugs under experimental and clinical research 1991;17(2):91-9.
1990: S H Gillespie; A J Baskerville; Robert N Davidson; David Felmingham; A D Bryceson
The serum rifabutin concentrations in a patient successfully treated for multi-resistant Mycobacterium tuberculosis infection.
The Journal of antimicrobial chemotherapy 1990;25(3):490-1.
1990: H Hassan; M D O'Hare; David Felmingham
In vitro activity of teicoplanin, vancomycin, A16686, clindamycin, erythromycin and fusidic acid against anaerobic bacteria.
Singapore medical journal 1990;31(1):56-8.
1990: M D O'Hare; G Ghosh; David Felmingham; Reuben N Grüneberg
In-vitro studies with ramoplanin (MDL 62,198): a novel lipoglycopeptide antimicrobial.
The Journal of antimicrobial chemotherapy 1990;25(2):217-20.
1990: David Felmingham; P Foxall; M O'Hare; Reuben N Grüneberg
The bactericidal activity of vancomycin and teicoplanin against Streptococcus pneumoniae.
Scandinavian journal of infectious diseases. Supplementum 1990;72():20-5.
1989: C Morran; C McArdle; L Pettitt; D Sleigh; C Gemmell; M Hichens; David Felmingham; G Tillotson
Pharmacokinetics of orally administered ciprofloxacin in abdominal surgery.
The American journal of medicine 1989;87(5A):86S-88S.
1989: P A Foxall; David Felmingham; Reuben N Grüneberg
Resistance studies with ofloxacin.
Journal of chemotherapy (Florence, Italy) 1989;1(4 Suppl):381-3.
1989: M D O'Hare; David Felmingham; Reuben N Grüneberg
In vitro bactericidal activity of the glycopeptide compounds vancomycin, teicoplanin and ramoplanin (A-16686/MDL 62,198).
Journal of chemotherapy (Florence, Italy) 1989;1(4 Suppl):210-1.
1989: David Felmingham; MJ Robbins; M D O'Hare; K Jones; Geoff L Ridgway; Reuben N Grüneberg
In vitro activity and synergy studies with fleroxacin.
Journal of chemotherapy (Florence, Italy) 1989;1(4 Suppl):162-4.
1989: MJ Robbins; A J Baskerville; M Sanghrajka; G Mumtaz; David Felmingham; Geoff L Ridgway; Reuben N Grüneberg
Comparative in vitro activity of lomefloxacin, a difluoro-quinolone.
Diagnostic microbiology and infectious disease 1989;12(3 Suppl):65S-76S.
1989: M D O'Hare; David Felmingham; Reuben N Grüneberg
The bactericidal activity of vancomycin and teicoplanin against methicillin-resistant strains of coagulase negative Staphylococcus spp.
The Journal of antimicrobial chemotherapy 1989;23(5):800-2.
1989: A P R Wilson; S Shankar; David Felmingham; Tom Treasure; Reuben N Grüneberg
Serum and tissue levels of teicoplanin during cardiac surgery: the effect of a high dose regimen.
The Journal of antimicrobial chemotherapy 1989;23(4):613-7.
1989: M K Arora; MJ Robbins; john holton; David Felmingham
In-vitro activity of the streptogramin group of antimicrobials against Corynebacterium jeikeium and D2 coryneform bacteria.
The Journal of antimicrobial chemotherapy 1989;23(3):458-60.
1989: David Felmingham; K Jones
In vitro activity of dactimicin and other aminoglycosides against bacteria producing aminoglycoside-modifying enzymes.
Drugs under experimental and clinical research 1989;15(3):133-6.
1989: David Felmingham; MJ Robbins; A J Baskerville; M D Sanghrajka; Geoff L Ridgway; Reuben N Grüneberg
Comparative in vitro activity of ciprofloxacin and other unrelated antimicrobials against bacterial respiratory tract pathogens.
Drugs under experimental and clinical research 1989;15(2):59-62.
1988: Reuben N Grüneberg; David Felmingham; M D O'Hare; MJ Robbins; K Perry; R A Wall; Geoff L Ridgway
The comparative in-vitro activity of ofloxacin.
The Journal of antimicrobial chemotherapy 1988;22 Suppl C():9-19.
1988: David Felmingham; P Foxall; M D O'Hare; G Webb; G Ghosh; Reuben N Grüneberg
Resistance studies with ofloxacin.
The Journal of antimicrobial chemotherapy 1988;22 Suppl C():27-34.
1988: A P R Wilson; David Felmingham; Reuben N Grüneberg; Tom Treasure; M F Sturridge
Contamination of blood during cardiopulmonary bypass: the effect of antibiotic prophylaxis.
The Journal of hospital infection 1988;12(1):35-42.
1988: G Mumtaz; Geoff L Ridgway; David Felmingham
In vitro activity of sulphamethoxazole/trimethoprim and sulfadoxine/pyrimethamine against Chlamydia trachomatis SA2f in McCoy cell culture.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1988;7(3):415-7.
1988: A P R Wilson; B Taylor; Tom Treasure; Reuben N Grüneberg; K Patton; David Felmingham; M F Sturridge
Antibiotic prophylaxis in cardiac surgery: serum and tissue levels of teicoplanin, flucloxacillin and tobramycin.
The Journal of antimicrobial chemotherapy 1988;21(2):201-12.
1988: A J Baskerville; David Felmingham; Reuben N Grüneberg
A high performance liquid chromatography method for the determination of FCE 22101, a novel penem antimicrobial, in serum.
Drugs under experimental and clinical research 1988;14(10):645-8.
1988: M D O'Hare; David Felmingham; Reuben N Grüneberg
The in vitro activity of ramoplanin (A-16686/MDL 62,198), vancomycin and teicoplanin against methicillin-susceptible and methicillin-resistant Staphylococcus spp.
Drugs under experimental and clinical research 1988;14(10):617-9.
1988: K Jones; David Felmingham; Geoff L Ridgway
In vitro activity of azithromycin (CP-62,993), a novel macrolide, against enteric pathogens.
Drugs under experimental and clinical research 1988;14(10):613-5.
1987: David Felmingham; K Solomonides; M D O'Hare; A P Wilson; Reuben N Grüneberg
The effect of medium and inoculum on the activity of vancomycin and teicoplanin against coagulase-negative staphylococci.
The Journal of antimicrobial chemotherapy 1987;20(4):609-10.
1987: M Robbins; R Marais; David Felmingham; Geoff L Ridgway
The in-vitro activity of doxycycline and minocycline against anaerobic bacteria.
The Journal of antimicrobial chemotherapy 1987;20(3):379-82.
1987: M Robbins; R Marais; A P Wilson; David Felmingham
Activity of sodium fusidate in vitro against anaerobic bacteria.
European journal of clinical microbiology 1987;6(3):326-7.
1987: David Felmingham; MJ Robbins; R Marais; Geoff L Ridgway; R N Gruneberg
The effect of carbon dioxide on the in vitro activity of erythromycin and RU-28965 against anaerobic bacteria.
Drugs under experimental and clinical research 1987;13(4):195-9.
1987: MJ Robbins; R Marais; David Felmingham; Geoff L Ridgway; Reuben N Grüneberg
In vitro activity of vancomycin and teicoplanin against anaerobic bacteria.
Drugs under experimental and clinical research 1987;13(9):551-4.
1987: K R Patton; A Beg; David Felmingham; Geoff L Ridgway; Reuben N Grüneberg
Determination of teicoplanin concentration in serum using a bioassay technique.
Drugs under experimental and clinical research 1987;13(9):547-50.
1986: A P Wilson; M D O'Hare; David Felmingham; Reuben N Grüneberg
Teicoplanin-resistant coagulase-negative staphylococcus.
Lancet 1986;2(8513):973.
1985: MJ Robbins; M D O'Hare; David Felmingham; Geoff L Ridgway; Reuben N Grüneberg
The comparative activity of twelve 4-quinolone antimicrobials against gram-positive and gram-negative anaerobes.
Drugs under experimental and clinical research 1985;11(7):431-4.
1985: David Felmingham; M D O'Hare; MJ Robbins; R A Wall; A H Williams; A W Cremer; Geoff L Ridgway; Reuben N Grüneberg
Comparative in vitro studies with 4-quinolone antimicrobials.
Drugs under experimental and clinical research 1985;11(5):317-29.
1985: Geoff L Ridgway; M D O'Hare; David Felmingham; Reuben N Grüneberg
The comparative activity of twelve 4-quinolone antimicrobials against Haemophilus influenzae and Streptococcus pneumoniae.
Drugs under experimental and clinical research 1985;11(4):259-62.
1985: M D O'Hare; David Felmingham; Geoff L Ridgway; Reuben N Grüneberg
The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens.
Drugs under experimental and clinical research 1985;11(4):253-7.